Search Results - "Peters, Mary Linton Bounetheau"

Immunohistochemical and genetic profiles do not predict behavior of mixed hepatocellular intrahepatic cholangiocarcinoma by Sucre, Santiago, Paredes, Rodrigo, Peters, Mary Linton Bounetheau

“…516 Background: Combined hepatocellular intrahepatic cholangiocarcinoma (HCC CC) is a rare tumor defined by pathologic characteristics of both hepatocellular…”
Get full text

PD-L1 as a predictor of chemo-immunotherapy response in biliary tract cancers: A systematic review and meta-analysis by Juarez, Juan Jose, Osataphan, Soravis Alm, Ponvilawan, Ben, Charoenngam, Nipith, Peters, Mary Linton Bounetheau

“…541 Background: Advanced biliary tract cancers (BTCs) are rare and aggressive malignancies with limited treatment options. Recently, immune checkpoint…”
Get full text

Molecular profiling as a predictor of treatment response and survival in unresectable pancreatic ductal adenocarcinoma by Paredes, Rodrigo, Banegas, Marcela, Sucre, Santiago, Ponce, Cristina, Rattani, Ahmed Anwer Ali, Peters, Mary Linton Bounetheau

“…e16279 Background: To date, few targetable mutations have been found to enhance PDAC treatment. Next-generation sequencing (NGS) of somatic mutation profiles…”
Get full text

Association between somatic mutation pathways and treatment response in patients with biliary tract cancers (BTCs) by Birda, Vaibhav, Osataphan, Soravis Alm, Lyon, James, Paredes, Rodrigo, Rattani, Ahmed Anwer Ali, Peters, Mary Linton Bounetheau

“…e16196 Background: Comprehensive somatic genomic profiling has become the standard of care for patients with BTCs, serving to identify targetable mutations and…”
Get full text

Comparison of neoadjuvant treatment modalities for locally advanced intrahepatic cholangiocarcinoma by Garita, Esteban, Tahir, Muhammad Mohid, Sucre, Santiago, Juarez, Juan Jose, Peters, Mary Linton Bounetheau, Sarwar, Ammar, Bullock, Andrea J.

“…510 Background: The only curative therapy available for intrahepatic cholangiocarcinoma (IHCC) is resection. Nonetheless, most patients (pts) are diagnosed at…”
Get full text

Cascade testing of first-degree relatives of patients with pancreatic cancer with confirmed germline genetic mutations: A simulation modeling study by Peters, Mary Linton Bounetheau, Davidi, Barak, Seguin, Claudia L., Eckel, Andrew, Pandharipande, Pari

“…10513 Background: Universal germline genetic testing is recommended for all patients with pancreatic ductal adenocarcinoma (PDAC). In addition to treatment…”
Get full text

COVID-19 clearance among patients with cancer during the Delta and Omicron waves by Avigan, Zachary M, Paredes, Rodrigo, Boussi, Leora S, Lam, Barbara, Shea, Meghan, Weinstock, Matthew, Peters, Mary Linton Bounetheau

“…42 Background: COVID-19 presents a particular challenge in oncology, as in-person visits and treatments can be delayed during infection and patients are at…”
Get full text

Uptake in genetic testing in patients with pancreatic cancer with oncologist-driven testing protocol by King, Traci, Widick, Page, Paredes, Rodrigo, Klein, Oliver, Krejdovsky, Jill, Tung, Nadine M., Peters, Mary Linton Bounetheau

“…33 Background: The objective was to compare the uptake of genetic testing in patients with pancreatic adenocarcinoma (PDAC) seen at a single center (1) before…”
Get full text

Number of subsequent treatments and time to recurrence in hepatocellular carcinoma by Juarez, Juan Jose, Birda, Vaibhav, Sucre, Santiago, Garita, Esteban, Pacheco-Barrios, Kevin, Paredes, Rodrigo, Bullock, Andrea J., Sarwar, Ammar, Peters, Mary Linton Bounetheau

“…526 Background: Hepatocellular carcinoma (HCC) is often managed with locoregional therapies including surgical resection, ablation, transcatheter arterial…”
Get full text

Association of immune related adverse events with superior outcomes in patients with hepatocellular carcinoma (HCC) treated with nivolumab by Ostios-Garcia, Lorena, Ramiro-Cortijo, David, Peters, Mary Linton Bounetheau, Bullock, Andrea J.

“…Abstract only e16630 Background: Nivolumab, an anti-PD1 antibody, is FDA approved in patients (pts) with HCC. Anti-PD-1 promotes hyperstimulation of host…”
Get full text

Time to COVID-19 RT-PCR clearance among patients with cancer by Xu, Wenxin, Piper-Vallillo, Andrew, Bindal, Poorva, Wischhusen, Jonathan W., Patel, Jaymin M., Costa, Daniel Botelho, Peters, Mary Linton Bounetheau

“…Abstract only 49 Background: COVID-19 in oncologic patients presents a clinical dilemma. To reduce the risk of adverse events as well as the risk of exposing…”
Get full text

GI oncology molecular tumor board: Fostering collaboration and clinical education for personalized therapy by Grossman, Joseph Elan, Bullock, Andrea J., Angarita, Susana, Bockorny, Bruno, Dayyani, Farshid, Hurley, Molly, McGregor, Kimberly, Pectasides, Eirini, Peters, Mary Linton Bounetheau, Reddy, Venkataprasanth P., Schlechter, Benjamin L., Tavallai, Mehrad, Zerillo, Jessica A.

“…Abstract only 11029 Background: In recent years, genomic profiling has become standard of care for several gastrointestinal (GI) cancers. In addition to…”
Get full text

A phase I study of LY3410738, a first-in-class covalent inhibitor of mutant IDH1 in cholangiocarcinoma and other advanced solid tumors by Pauff, James Michael, Papadopoulos, Kyriakos P., Janku, Filip, Turk, Anita Ahmed, Goyal, Lipika, Shroff, Rachna T., Shimizu, Toshio, Ikeda, Masafumi, Azad, Nilofer Saba, Cleary, James M., Peters, Mary Linton Bounetheau, Borad, Mitesh J., Jaeckle, Kurt A., Kizilbash, Sani Haider, Tupper, Rebecca, Furin, Carrie E., Hanley, Matthew P., Hill, Elizabeth Goodwin, Xu, Xiaojian, Harding, James J.

“…Abstract only TPS350 Background: Mutations in isocitrate dehydrogenase 1 (mIDH1) are found in approximately 20-30% of patients with intrahepatic…”
Get full text

Comparison of the clinical features, treatment patterns, and tumor mutations of patients with intrahepatic (ICC) and extrahepatic (ECC) cholangiocarcinoma by Pappas, Leon, Reyes, Stephanie, Lanka, Aishwarya, Shroff, Rachna T., Le, Tri Minh, Rahma, Osama E., Bocobo, Andrea Grace, Borad, Mitesh J., DeLeon, Thomas, Mody, Kabir, Roth, Marc Thomas, Peters, Mary Linton Bounetheau, Goff, Laura Williams, Boyhen, Kylie, VanCott, Christine, Horick, Nora, Zhu, Andrew X., Javle, Milind M., Kelley, Robin Kate, Goyal, Lipika

“…Abstract only 580 Background: Though studies indicate that the genomic profiles of ICC and ECC are distinct, the clinical features that differentiate them…”
Get full text

Germline genetic testing in unselected pancreatic ductal adenocarcinoma (PDAC) patients by Peters, Mary Linton Bounetheau, Brand, Randall, Borazanci, Erkut Hasan, Stobie, Lindsey, Dudley, Beth, Karloski, Eve, Moser, A James, Colvin, Arlene, Lim, Cynthia, Bahary, Nathan, Sun, Weijing, Rhee, John C., Lembersky, Barry C., Stoller, Ronald G., LaDuca, Holly, Dolinsky, Jill S, Dalton, Emily, Speare, Virginia, Black, Mary Helen, Tung, Nadine M.

“…Abstract only 1501 Background: The aim of this study is to assess the prevalence of known heritable germline mutations in unselected PDAC patients and to…”
Get full text